AREDS2 multivitamin (full formulation)
Multi-nutrient formula tested in the AREDS2 RCT for people with intermediate AMD; Cochrane-reviewed antioxidant formulas modestly slow progression to late AMD.
- Evidence
- Moderate evidenceGRADE certainty: Moderate
- Typical dose
- AREDS2 daily formula: vit C 500 mg, vit E 400 IU, zinc oxide 25–80 mg, cupric oxide 2 mg, lutein 10 mg, zeaxanthin 2 mg
- Time to effect
- AMD progression endpoints assessed over 3–5 years
- Safety
- Has documented cautions
Evidence ratings summarise published research on AREDS2 multivitamin (full formulation) in general. They are not a health claim for any product and not advice for any individual. Talk to your doctor before starting anything new, especially if you take medication.
Ask about AREDS2 multivitamin (full formulation)
Interactions
Taking any medication?
Check AREDS2 multivitamin (full formulation) against it.
Why
The AREDS2 formula is the specific multi-nutrient combination tested in the Age-Related Eye Disease Study 2 (Chew JAMA 2013): vitamin C 500 mg, vitamin E 400 IU, zinc oxide 80 mg (later reduced to 25 mg without efficacy loss), cupric oxide 2 mg, lutein 10 mg, zeaxanthin 2 mg. Designed for adults with intermediate or advanced AMD in at least one eye. Cochrane reviews of antioxidant vitamin and mineral formulas found moderate-certainty evidence of slower progression to late AMD, with the absolute benefit concentrated in people at higher risk. Adding lutein/zeaxanthin or omega-3 did not significantly lower progression in the primary AREDS2 analysis, and NICE has not recommended these supplements. Beta-carotene from the original AREDS formula was removed because of lung-cancer risk in smokers.
How it works
Combined antioxidant (vit C, E) and trace-mineral (zinc, copper) effects on macular oxidative stress and inflammation; lutein/zeaxanthin specifically concentrate in macular pigment.
Expected onset · AMD progression endpoints assessed over 3–5 years
How to take
Dosage
AREDS2 daily formula: vit C 500 mg, vit E 400 IU, zinc oxide 25–80 mg, cupric oxide 2 mg, lutein 10 mg, zeaxanthin 2 mg. Once or split twice daily with food.
Timing
With meals; split twice daily for better tolerability
On the label
Look for 'AREDS2 formula' explicitly, the specific dosing matters and varies between OTC products.
Studied in
Adults with intermediate (large drusen) or advanced AMD in one eye; under ophthalmology guidance to confirm the staging and the appropriateness of supplementation.
Safety
Evidence
Evans 2023 Cochrane review (26 RCTs, 11,952 people with AMD): antioxidant vitamin and mineral supplements were followed by less progression to late AMD (OR 0.72, moderate-certainty), roughly 78 fewer cases per 1,000 in intermediate AMD. In the AREDS2 10-year follow-up, lung cancer odds were higher with beta carotene (OR 1.82) than with lutein/zeaxanthin (not significant). NICE (NG82, 2018) called the evidence unclear.
GRADE certainty: Moderate — reported by Cochrane 2023 (Evans and Lawrenson)
- AREDS2 Research Group, JAMA 2013, lutein + zeaxanthin and omega-3 fatty acids for AMD: AREDS2 RCT (n=4,203)
- AREDS Research Group, Arch Ophthalmol 2001, a randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for AMD and vision loss: AREDS report no. 8
- Evans JR, Lawrenson JG, Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration, Cochrane Database Syst Rev 2023
- Evans JR, Lawrenson JG, Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration, Cochrane Database Syst Rev 2017
- Age-Related Eye Disease Study 2 (AREDS2) Research Group et al., Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3, JAMA Ophthalmol 2014
- Chew EY et al., Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28, JAMA Ophthalmol 2022
- NICE guideline (2018): Age-related macular degeneration (NG82)
Questions people ask
Does AREDS2 multivitamin (full formulation) work?
Evans 2023 Cochrane review (26 RCTs, 11,952 people with AMD): antioxidant vitamin and mineral supplements were followed by less progression to late AMD (OR 0.72, moderate-certainty), roughly 78 fewer cases per 1,000 in intermediate AMD. In the AREDS2 10-year follow-up, lung cancer odds were higher with beta carotene (OR 1.82) than with lutein/zeaxanthin (not significant). NICE (NG82, 2018) called the evidence unclear. Certainty of the evidence: Moderate, reported by Cochrane 2023 (Evans and Lawrenson).
How is AREDS2 multivitamin (full formulation) taken?
AREDS2 daily formula: vit C 500 mg, vit E 400 IU, zinc oxide 25–80 mg, cupric oxide 2 mg, lutein 10 mg, zeaxanthin 2 mg. Once or split twice daily with food. Timing: With meals; split twice daily for better tolerability. Ranges are those reported in the cited sources, not individual advice; talk to your doctor or pharmacist before starting, especially if you take medication.
Are there interactions or cautions?
Zinc dose can cause GI upset and copper depletion (hence the cupric oxide co-prescription). Vitamin E at 400 IU has been weakly associated with mortality in some meta-analyses. Discuss with ophthalmologist in shared decision. Not for primary prevention without AMD diagnosis, only studied in established AMD. Smokers: AREDS2 (not AREDS1) is the appropriate formula (no beta-carotene). Pregnancy: not indicated. Documented drug and supplement interactions can be looked up in the free interaction reference.
What is the evidence based on?
Sources: AREDS2 Research Group, JAMA 2013, lutein + zeaxanthin and omega-3 fatty acids for AMD: AREDS2 RCT (n=4,203); AREDS Research Group, Arch Ophthalmol 2001, a randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for AMD and vision loss: AREDS report no. 8; Evans JR, Lawrenson JG, Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration, Cochrane Database Syst Rev 2023; Evans JR, Lawrenson JG, Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration, Cochrane Database Syst Rev 2017; Age-Related Eye Disease Study 2 (AREDS2) Research Group et al., Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3, JAMA Ophthalmol 2014; Chew EY et al., Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28, JAMA Ophthalmol 2022; NICE guideline (2018): Age-related macular degeneration (NG82).
One evidence finding a day, like this one: follow Healicus on Threads or Bluesky.